Since its first description 25 years ago, 1 ischaemic preconditioning has become one of the most studied protective interventions in the cardiovascular field, in part due to its universality (it is effective in all animal species tested, including humans, and in different organs) and reproducibility (it has only a weak dependence on the ischaemic protocol applied before sustained ischaemia or on the duration and severity of the ischaemic insult). The identification of the involved signalling pathways and end-effectors was expected to have important therapeutic implications. However, despite the enormous amount of experimental data, our understanding of the cellular mechanisms responsible for preconditioning protection remains incomplete and at some points controversial. The reason for this failure is demonstrated by the large number of publications describing different molecular pathways involved in protection, some of them acting in parallel or being redundant or dispensable, whereas others appear to be additive or to operate in series, making it very difficult to integrate them into a comprehensive survival pathway. No less important was the lack of understanding of the ultimate mechanisms (end-effectors) by which these signalling pathways reduce cell death. End-effectors of preconditioning have to be molecules downstream the signalling pathway directly involved in cell death. They have the greatest therapeutic interest for obvious reasons; however, their identification has proved not to be a trivial task, and multiple candidates have been proposed. Often, the triggers, mediators, and end-effectors of preconditioning protection have been difficult to differentiate. An example of this confusion is the mitochondrial K ATP channels. During the past decade, the idea that mitochondrial K ATP channels could be important players in preconditioning protection emerged as a dominant concept. They were proposed to trigger the ischaemic preconditioning cascade, 2 to participate in the ROS-dependent signalling pathways, 3, 4 and also to act as the end-effectors of cardioprotection, 5, 6 presumably by improving energy transfer efficiency 7 or by attenuating mitochondrial Ca 2+ overload during reperfusion. 8 However, experimental evidence could not definitely prove that mitochondrial K ATP channels may be the end-effectors of cardioprotection, their molecular identity remains largely unknown, and even their existence is debated. Cell death induced by an ischaemic episode occurs mainly in the first minutes of reperfusion. Excessive contractile activation (hypercontracture) and proteolytic activation secondary to elevated cytosolic Ca 2+ concentration have been shown to play a causative role in necrotic cell death, 10 -12 and contractile inhibition has been proposed to be an end-effector of ischaemic preconditioning. 13, 14 Ischaemic preconditioning preserves cGMP-PKG signalling, which, in turn, improves Ca 2+ handling and cell survival by targeting intracellular molecules known to attenuate sarcoplasmic reticulum-driven Ca 2+ oscillations and hypercontracture 15 -17 and to reduce the sensitivity of myofilaments to Ca 2+ . 18 Proteolysis mediated by Ca 2+ -dependent calpain activation has also been proposed to be reduced by previous ischaemic preconditioning, 19 which results in attenuated sarcolemmal Na + pump dysfunction, reduced Ca 2+ overload secondary to reverse Na + -Ca 2+ exchange, preserved sarcolemmal integrity, and less hypercontracture. 20 Other potential end-effectors of ischaemic preconditioning are gap junction channels-involved in the propagation of cell death during reperfusion, 21 membrane hemichannels-whose uncontrolled opening may trigger massive cell swelling and death, 22 and connexin43-recently described to participate in cardioprotection by mechanisms not related to intercellular communication but to its mitochondrial localization. 23, 24 In 2002, Hausenloy et al. 25 published the first experimental evidence of the involvement of mitochondrial permeability transition in the protection afforded by ischaemic and pharmacological preconditioning. In that study, isolated perfused rat hearts were subjected to 35 min regional ischaemia and 120 min reperfusion with or without
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a previous preconditioning stimulus. Several drugs were tested alone or in combination, including two different agonists known to protect the heart when administered before ischaemia ('pharmacological preconditioning'), the mitochondrial K ATP channel opener diazoxide and the adenosine A1 receptor agonist CCPA, together with drugs inhibiting (CsA) or inducing (atractyloside) mitochondrial permeability transition or preventing the opening of mitochondrial K ATP channels (5-HD). The results indicated that the protection afforded by both ischaemic and pharmacological preconditioning against reperfusion-induced cell death was mediated by its inhibitory effect against mitochondrial permeabilization. Whenever atractyloside was present along with the protective stimulus, infarct size reduction was abrogated, although it did not have any effect when administered alone. These results were further supported by experiments in isolated mitochondria in which interventions previously shown to reduce infarct size were also capable of decreasing the in vitro mitochondrial calcein release stimulated by Ca 2+ overload.
In their paper, 25 the authors speculated whether prevention of mitochondrial permeability transition could become the new paradigm for myocardial preconditioning, and 10 years later mitochondrial permeability transition remains at the cutting edge in the field of myocardial protection. Remarkably, some years after the publication of their seminal paper, the same group described the specific role of cyclophilin-D, a putative component of the mitochondrial permeability transition pore, as the molecule triggering the preconditioning signalling cascade by a mechanism involving reversible non-pathological mitochondrial permeabilization. 26 In a few years, mitochondrial permeability transition became not only the potential end-effector of preconditioning-as well as other cardioprotective manoeuvresbut also the trigger of protection, an effect as paradoxical as the preconditioning phenomenon itself. Long lasting or flickering opening of the mitochondrial permeability transition pore can be either lethal or protective, and the inhibition of one or the other mode of mitochondrial permeabilization may represent two faces of the same coin-the pathophysiological mechanism of ischaemic preconditioning. Mitochondrial permeability transition has attracted much attention in the past decade as one of the critical determinants of cell death during ischaemia reperfusion. 27 A sustained increase in mitochondrial permeability results in mitochondrial matrix swelling and energetic collapse, incompatible with cell life. As such, its contribution to necrotic cell death during reperfusion has been unambiguously demonstrated in several studies. 27 Different components involved in its structure and regulation, such as adenine nucleotide tranlocator, 28 cyclophilin D, 29 and voltage-dependent anion channels, 30 have aroused great interest as potential therapeutic targets. However, the precise molecular identity of mitochondrial permeability transition is still unknown and some of the previously described conformational molecules turned out to be dispensable for mitochondrial permeabilization. 31, 32 The landmark paper by Hausenloy et al. 25 proposed a unifying mechanism for different cardioprotective interventions that could explain the reduction in cell death after an ischaemic episode. Since its publication, many original articles, reviews, and editorials have discussed the decisive role the prevention of mitochondrial permeability transition has in the improvement of cell survival secondary to ischaemic preconditioning. 33 -37 The participation of mitochondria permeability transition as the triggering and effector of preconditioning protection has not lost validity at present; on the contrary, it has been extended to postconditioning protection and translated to patients. 38 However, many questions remain unsolved. Whether or not mitochondrial permeability transition is a multiprotein channel or merely reflects an increased permeability stage of otherwise damaged mitochondria has not yet been clarified, nor has the molecular mechanism responsible for its causative role in acute sarcolemmal rupture been defined. Also, its potential modulation by other factors, like ageing, diabetes, and other comorbidities that clearly reduce the effectiveness of preconditioning cardioprotection, is far from well characterized and is the object of much scientific interest. The paper from Hausenloy et al. 25 was not free of limitations. Many would have said that the most important aspect was that the authors relied exclusively on pharmacological interventions and did not take advantage of genetically modified animals. However, it was an important paper because it opened a new area of research and helped to set up a new paradigm in cardiovascular science.
